Navigation Links
Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Date:11/19/2009

MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that its corporate presentation will be webcast live during the 21st Annual Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 9:00 a.m. Eastern Time. The presentation will be webcast from The New York Palace Hotel in New York and will be presented by Thomas B. King, Alexza President and CEO.

To access the live presentation via the Web, please go to the direct conference link located at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ALXA&item_id=2539597 or at the Alexza Investor Relations tab at www.alexza.com.

A replay of the Webcast will be made available approximately 24 hours after the live presentation and the replay will be archived for 14 days.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting a New Drug Application submission in early 2010.

Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.

AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.

Safe Harbor Statement

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
2. Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
3. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
4. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
5. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
6. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
7. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
8. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
9. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
10. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
11. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... July 11, 2017 Zymo Research Corp., also known as ,The ... quantify biological aging in a precise manner using the myDNAge ™ ... , a professor of human genetics and biostatistics at the David ... Public Health , Zymo Research,s proprietary DNAge ™ technology is used ... ...
(Date:7/11/2017)...  Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe ... from painful intercourse and other painful pelvic pain conditions such as pelvic ... ... ... Florida -based start-up company, VuVatech LLC, fills a void in the ...
(Date:7/10/2017)... 10, 2017  BDI Group subsidiary Pathway Purchasing ... services organization serving specialty pharmacies, home infusion companies ... four significant, value-added member programs designed to help ... reimbursement and improve access and affordability for patients ... Pathway has ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... There’s a lot of confusing lingo out there ... the same thing. But it’s crucial to understand both the differences and similarities between ... Kaixuan Liu, MD, PhD, founder and president of Atlantic Spine Center . ...
(Date:7/20/2017)... ... , ... LINET, an international leader in healthcare technology and a global supplier ... birthing bed. , Perfectly suitable for labor, delivery, recovery and postpartum; the revolutionary design ... every phase of childbirth. The AVE 2 has many features that help make the ...
(Date:7/20/2017)... ... July 19, 2017 , ... Med Tech Solutions (MTS), a leading health ... business unit of Constellation Inc., a move that will help the company better serve ... St. Louis, the acquisition is expected to help MTS expand its presence ...
(Date:7/20/2017)... ... 2017 , ... A July 7th article on ... veins in some patients, according to medical experts. Washington State medical clinic Northwest ... sitting or standing, or regularly nicking yourself while shaving your legs, and taking ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... device compliance and commercialization, has just announced two more sessions of its “From ... engineering into risk management activities. Led by David Cronin, Cognition’s CEO, the half-hour ...
Breaking Medicine News(10 mins):